Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Rare genetic diseases stories

Nov 1, 2026

Setara Biosciences launches with $90M for rare disease drug development

Setara Biosciences has started operations with $90 million in funding and a lead drug candidate already in clinical trials for Charcot-Marie-Tooth disease type 2C and overactive bladder.

Nov 1, 2026·4 sources
00
Oct 29, 2026

University of Eastern Finland identifies vitamin transporter protein for brain drug delivery

Researchers at the University of Eastern Finland have identified the SMVT transporter protein that can improve creatine delivery to the brain and potentially enable new therapies targeting the central nervous system. The discovery addresses one of medicine's greatest challenges: delivering drugs across the blood-brain barrier.

Oct 29, 2026·4 sources
00
Sep 22, 2026

Otsuka and Ionis' ulefnersen meets primary endpoint in phase 3 ALS trial

Otsuka Pharmaceutical and Ionis Pharmaceuticals announced their experimental drug ulefnersen met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis (ALS), showing improvements in functional impairment and survival. The partners plan to approach the FDA to determine potential regulatory pathways.

Sep 22, 2026·6 sources
00
Aug 18, 2026

Leo Pharma acquires worldwide rights to dersimelagon for up to $435M

Danish drugmaker Leo Pharma agreed to acquire worldwide rights to dersimelagon, a late-stage drug candidate for two rare genetic skin diseases, from Tanabe Pharma for up to $435 million in upfront and milestone payments.

Aug 18, 2026·2 sources
00
Aug 10, 2026

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.

Aug 10, 2026·6 sources
00

Top claims

  • ▪Setara Biosciences applies a strategy that starts with rare genetic diseases to identify targets and then expands those biological insights to treat broader, more prevalent conditions
  • ▪Setara Biosciences completed the healthy volunteer Phase 1 trial of STAR-0871 and plans to expand into a Phase 1b study in Charcot-Marie-Tooth disease type 2C patients in 2027
  • ▪Investors participating in Setara Biosciences' $90 million Series A financing included Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures, and Jazz Pharmaceuticals

Subtopics

Drug development4Clinical trials3Rare diseases3Drug Approval and Clinical Trials2Drug Policy, Pricing & Approval2Genetic disorders2Mergers & acquisitions (M&A)2Neurological disorders2Pharma2Pharmaceutical Industry2Biomedical research1Biotech startup1Biotechnology1Clinical Trial Design & Evaluation1Clinical trial endpoints1Corporate strategy1Drug discovery1Fast track designation1Medical research1Neuroscience1Orphan drug designation1Venture capital funding1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories